Free Trial

Protalix BioTherapeutics (PLX) Competitors

Protalix BioTherapeutics logo
$1.59 -0.01 (-0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 0.00 (0.00%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLX vs. EOLS, ALMS, CMPX, TECX, KOD, ETON, ARCT, RGNX, ITOS, and ESPR

Should you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Evolus (EOLS), Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

Protalix BioTherapeutics vs. Its Competitors

Protalix BioTherapeutics (NYSE:PLX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Evolus had 9 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 9 mentions for Evolus and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.73 beat Evolus' score of 1.64 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Protalix BioTherapeutics Very Positive
Evolus Very Positive

Protalix BioTherapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Protalix BioTherapeutics has a net margin of -21.03% compared to Evolus' net margin of -22.31%. Protalix BioTherapeutics' return on equity of -30.89% beat Evolus' return on equity.

Company Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics-21.03% -30.89% -11.74%
Evolus -22.31%-759.04%-24.63%

Protalix BioTherapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protalix BioTherapeutics$61.95M2.05$8.31M$0.0722.71
Evolus$266.27M1.82-$50.42M-$0.98-7.66

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 6.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Protalix BioTherapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 843.40%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 182.96%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Evolus
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Protalix BioTherapeutics beats Evolus on 10 of the 16 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLX vs. The Competition

MetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$126.77M$282.63M$5.76B$21.30B
Dividend YieldN/AN/A6.66%3.49%
P/E Ratio-12.23N/A83.0129.44
Price / Sales2.05477.76503.0364.27
Price / Cash17.8022.4425.7018.29
Price / Book3.3811.4110.795.30
Net Income$8.31M-$115.81M$3.29B$998.51M
7 Day Performance2.58%2.35%0.02%0.12%
1 Month Performance6.00%1.01%7.06%5.75%
1 Year Performance57.43%-14.14%50.09%14.88%

Protalix BioTherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLX
Protalix BioTherapeutics
3.3776 of 5 stars
$1.59
-0.6%
$15.00
+843.4%
+49.5%$126.77M$61.95M-12.23200Positive News
EOLS
Evolus
4.5294 of 5 stars
$7.63
+1.5%
$21.25
+178.5%
-52.6%$493.55M$266.27M-7.79170News Coverage
Positive News
Short Interest ↓
ALMS
Alumis
2.5714 of 5 stars
$4.64
-1.3%
$20.17
+334.6%
-61.6%$482.86MN/A0.00N/A
CMPX
Compass Therapeutics
2.5337 of 5 stars
$3.49
flat
$12.89
+269.3%
+123.2%$482.61M$850K-7.7620News Coverage
Positive News
TECX
Tectonic Therapeutic
2.2755 of 5 stars
$25.54
-0.1%
$80.33
+214.5%
-14.9%$477.91MN/A-6.32120News Coverage
Positive News
Analyst Forecast
KOD
Kodiak Sciences
3.8097 of 5 stars
$9.04
+0.8%
$11.75
+30.0%
+254.1%$477.51MN/A-2.3890
ETON
Eton Pharmaceuticals
2.5725 of 5 stars
$17.31
+0.2%
$29.67
+71.4%
+279.3%$464.21M$39.01M-108.1920News Coverage
Positive News
ARCT
Arcturus Therapeutics
3.6463 of 5 stars
$17.01
-1.7%
$50.57
+197.3%
-11.3%$461.90M$152.31M-7.63180News Coverage
Positive News
Analyst Forecast
RGNX
REGENXBIO
4.3829 of 5 stars
$8.93
-0.9%
$28.38
+217.7%
-13.1%$451.09M$83.33M-2.60370News Coverage
Positive News
ITOS
iTeos Therapeutics
3.5091 of 5 stars
$10.15
flat
$15.50
+52.7%
N/A$448.68M$35M-2.1790News Coverage
Short Interest ↓
ESPR
Esperion Therapeutics
3.8844 of 5 stars
$2.22
+0.5%
$7.00
+215.3%
+32.8%$447.60M$332.31M-4.53200Options Volume

Related Companies and Tools


This page (NYSE:PLX) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners